Cargando…

Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications

Survivin (BIRC5) is a tumor-associated antigen (TAA) overexpressed in various tumors but present at low to undetectable levels in normal tissue. Survivin is known to have a high expression in breast cancer (e.g., Ductal Carcinoma in situ (DCIS) and triple negative breast cancer). Previous studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wright, Sharon, Burkholtz, Scott R., Zelinsky, Cathy, Wittman, Connor, Carback, Richard T., Harris, Paul E., Blankenberg, Tikoes, Herst, Charles V., Rubsamen, Reid M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380623/ https://www.ncbi.nlm.nih.gov/pubmed/37511584 http://dx.doi.org/10.3390/ijms241411827

Ejemplares similares

Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study
por: Burkholz, Scott R., et al.
Publicado: (2023)

A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
por: Harris, Paul E., et al.
Publicado: (2021)

Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome
por: Rubsamen, Reid, et al.
Publicado: (2020)

Analysis of well-annotated next-generation sequencing data reveals increasing cases of SARS-CoV-2 reinfection with Omicron
por: Burkholz, Scott, et al.
Publicado: (2023)

Paired SARS-CoV-2 spike protein mutations observed during ongoing SARS-CoV-2 viral transfer from humans to minks and back to humans
por: Burkholz, Scott, et al.
Publicado: (2021)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Radiomics in immuno-oncology
por: Bodalal, Z., et al.
Publicado: (2021)

The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019)

Advancing translational research for colorectal immuno-oncology
por: Thomas, Elaine M., et al.
Publicado: (2023)

An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design
por: Herst, C.V., et al.
Publicado: (2020)

Mevalonate Metabolism in Immuno-Oncology
por: Gruenbacher, Georg, et al.
Publicado: (2017)

Immuno-Oncology Essentials: An Overview
por: Hoffner, Brianna
Publicado: (2019)

Multiplex imaging in immuno-oncology
por: Zhao, Chen, et al.
Publicado: (2023)

Immuno-oncology combinations: raising the tail of the survival curve
por: Harris, Samuel J., et al.
Publicado: (2016)

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology
por: Ji, Yan, et al.
Publicado: (2018)

Statistical issues and challenges in immuno-oncology
por: Chen, Tai-Tsang
Publicado: (2013)

Immunotherapies and Combination Strategies for Immuno-Oncology
por: Barbari, Cody, et al.
Publicado: (2020)

Necroptosis in Immuno-Oncology and Cancer Immunotherapy
por: Sprooten, Jenny, et al.
Publicado: (2020)

Immuno-oncology for B-cell lymphomas
por: Choi, Yoon Seok
Publicado: (2021)

Virus-Based Immuno-Oncology Models
por: Sitta, Juliana, et al.
Publicado: (2022)

Organoids as an Enabler of Precision Immuno-Oncology
por: Zhao, Junzhe, et al.
Publicado: (2023)

Single-Cell Analysis in Immuno-Oncology
por: Christodoulou, Maria-Ioanna, et al.
Publicado: (2023)

The Role of PRMT5 in Immuno-Oncology
por: Abe, Yoshinori, et al.
Publicado: (2023)

Racing CARs to veterinary immuno-oncology
por: Cockey, James R., et al.
Publicado: (2023)

Survivin – biology and potential as a therapeutic target in oncology
por: Cheung, Chun Hei Antonio, et al.
Publicado: (2013)

Prognostic Value and Targeted Inhibition of Survivin Expression in Esophageal Adenocarcinoma and Cancer-Adjacent Squamous Epithelium
por: Malhotra, Usha, et al.
Publicado: (2013)

An Approach for a Synthetic CTL Vaccine Design against Zika Flavivirus Using Class I and Class II Epitopes Identified by Computer Modeling
por: Cunha-Neto, Edecio, et al.
Publicado: (2017)

Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
por: Holmen Olofsson, Gitte, et al.
Publicado: (2020)

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends
por: Posa, Alessandro, et al.
Publicado: (2023)

Immuno-Oncology: Emerging Targets and Combination Therapies
por: Marshall, Henry T., et al.
Publicado: (2018)

Current markers and their value in the era of immuno-oncology
por: von Rundstedt, Friedrich-Carl, et al.
Publicado: (2017)

Radiotherapy as a New Player in Immuno-Oncology
por: Wang, Shang-Jui, et al.
Publicado: (2018)

Quantitative Translation in Immuno‐Oncology Research and Development
por: Bottino, Dean, et al.
Publicado: (2020)

Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019)

Immunodynamics of explanted human tumors for immuno‐oncology
por: Dubuisson, Agathe, et al.
Publicado: (2020)

Lights and Shadows in Immuno-Oncology Drug Development
por: Bergamino Sirvén, Milana, et al.
Publicado: (2021)

The perplexing role of immuno-oncology drugs in osteosarcoma
por: Smrke, Alannah, et al.
Publicado: (2021)

Concepts and Applications of Information Theory to Immuno-Oncology
por: Karolak, Aleksandra, et al.
Publicado: (2021)

Ironing out exercise on immuno-oncological outcomes
por: Soh, Janjira, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9pk456qeiqfi002silqqitq6bc